Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
This blog post will cover the science behind incretin-based therapies, what is currently known and what the future of incretin-based drug development might look like
The cumulative incidence rates of NAION for the semaglutide and nonGLP-1 RA cohorts over 36 months were 8.9% (95% confidence interval [CI], 4.5%-13.1%) and 1.8% (95% CI, 0%-3.5%), respectively. The analysis showed that patients treated with semaglutide had a higher risk of developing NAION compared with non-GLP-1 RA antidiabetes medications (hazard ratio [HR], 4.28
Tao L, Qu X, Zhang Y, Song Y, Zhang SX
The glutathione system: a new drug target in neuroimmune disorders
& Sun, H
Of these, 14,488 person-trials initiated GLP-1RA during a median follow-up of 38 (interquartile range: 1864) months
US$ 27.21
US$ 22.49
US$ 26.74
US$ 21.41
US$ 28.42
